The following members of the executive team are the original founders of
Breath Diagnostics and each has been instrumental in the design and testing of the technologies and
application of OneBreath™.
Michael Bousamra II, MD
Dr. Bousamra is a co-founder and the president of Breath Diagnostics. He is responsible for developing
the idea of breath analysis for lung cancer detection. Dr. Bousamra is an Associate Professor of
Cardiovascular and Thoracic Surgery at the University of Louisville School of Medicine.
Past professional appointments include President of the Jewish Hospital
Medical Staff in addition to service on numerous advisory, steering and hospital administrative
committees, notably the Executive Committee at JHSMH, the Operating Committee at Jewish Hospital and a
host of academic appointments. A prolific author and presenter, Dr. Bousamra holds patents on methods
to detect cancer in animals and exhaled breath sampling method, device and analysis.
Michael H. Nantz, Ph.D.
Dr. Nantz is a Co-Founder of Breath Diagnostics. He was instrumental in designing aminooxy compound
ATM, a critical component of the microreactor used to capture the volatile organic compounds found in
lung cancers. Dr. Nantz earned his Ph.D. in 1987 from Purdue University working in the field of natural
product synthesis and he explored asymmetric synthesis as a postdoctoral researcher at M.I.T.
He came to the University of Louisville from the University of California,
Davis where he focused on organic synthesis for seventeen years. During his career, and now as the
Chairman of the Department of Chemistry at UofL, he mentored 25 Ph.D. graduates, published over 130
research articles, obtained 13 US patents, and co-authored two textbooks on organic chemistry.
Dr. Xiao-An (Sean) Fu, Ph.D.
Dr. Fu, serves as vice president and is responsible for developing the microchip concentration device
that is critical in the capture of the rare volatile organic compounds associated with cancer in breath.
He is an Associate Professor of Chemical Engineering at the University of Louisville.
Before joining the faculty of the University of Louisville in 2008 he was
a researcher in the Department of Electrical Engineering and Computer Science at Case Western Reserve
University. He invented a process for deposition of low stress polycrystalline SiC suitable as MEMS
structure materials. Among his many research interests is breath analysis for the development of a
noninvasive diagnostic tool for detection of early lung cancer, trace gas detection, active tuberculosis
and other pulmonary diseases.
Victor van Berkel, MD, Ph.D.
Dr. van Berkel is the secretary of Breath Diagnostics and is responsible for clinical trial data
coordination along with the recruitment of breath analysis patients and controls for studies. Dr. van
Berkel is an Associate Professor of Surgery in the Department of Cardiovascular and Thoracic Surgery and
the Director of the lung transplant program at the University of Louisville.
His clinical practice focuses on thoracic malignancies. After completing
his undergraduate training at MIT, Dr. van Berkel earned both his MD and Ph.D. at Washington University
in St. Louis prior to completing a fellowship in cardio-thoracic surgery. His general surgery residency
was completed at Harvard Medical School. Dr. van Berkel is an active author and lecturer and his research
interests include utilization of breath analysis to detect early stage lung cancer.
Richard Rummel, CEO
Richard Rummel has been the CEO of Breath Diagnostics since April 2015. His experience includes over
28 years of medical device experience in device sales, new product development and multiple product
launches. This is his fourth medical company startup with which he has worked.
He received his Bachelors in Science, Biology, from Hampden-Sydney College, Hampden-Sydney, Virginia,
May 1982. He began his career in the medical device industry with Johnson & Johnson in 1988 for nine
years prior to working with Elekta, Inc. He started his first company in 1998. Richard is a specialist in
strategic market analysis and market development with particular emphasis in changes resulting from the
Affordable Care Act.